BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having surveyed 35 key opinion leaders who treat a total of 6,200 acute pain patients each month on their expectations for Journavx usage, the firm now estimates FY25 sales of $100M, up from $42M previously, and peak U.S. sales of $1.5B in 2032, up from a prior forecast of $1.2B in 2033, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals’ Journavx: Strong Demand and Positive Outlook Drive Buy Rating
- Vertex Pharmaceuticals: Advancements in T1D Program and Strategic Focus on Innovative Therapies Justify Buy Rating
- Vertex Pharmaceuticals: Strategic Advancements and Promising Market Potential Drive Buy Rating
- Vertex Pharmaceuticals pursuing research-stage T1Dd programs
- Vertex Pharmaceuticals says VX-264 study did not meet primary endpoint